Australia Tga Medical Device Registration Service

Scope and evidence must be confirmed before any paid tests or filings.

An Australia TGA medical device registration filing is not just a form submission. The filing has to connect the correct Australian sponsor, the correct “kind of medical device”, the Australian classification, acceptable manufacturer evidence and a consistent set of product information. If those elements do not align, the application can fail preliminary assessment or be delayed during an application audit.

This page focuses on execution: what must be prepared, who is responsible for each input, how the ARTG inclusion application moves through TGA Business Services (TBS), and what has to remain controlled after inclusion. Broader market-entry strategy belongs on the Australia product compliance and market access page.

Start with the filing route, not the TBS form

Before anyone opens an inclusion application, confirm three gating points: whether the product actually needs ARTG inclusion, how the device is classified in Australia, and what constitutes the “kind of medical device” being filed. TGA states that most medical devices must be included in the Australian Register of Therapeutic Goods (ARTG) before supply, but exclusions and exemptions exist and some access pathways operate outside ordinary inclusion.

Gate	What must be established	Filing consequence
Regulatory status	Is the product a medical device, and is ordinary ARTG inclusion required?	Do not file an ordinary inclusion application until an exclusion, exemption or special-access issue has been resolved.
Australian classification	Classify under Australian rules using the manufacturer’s intended purpose and device characteristics.	The class drives the application path, evidence and possible audit exposure.
Kind of device	Confirm the sponsor, manufacturer, classification and GMDN term; for specified high-risk groupings, UPI is also relevant.	These attributes determine whether products can sit under one ARTG entry or require separate entries.
Regulatory evidence	Identify the conformity assessment / overseas market-authorisation evidence that can support the Australian filing.	Where Manufacturer Evidence is required, it must be accepted in TBS before the inclusion application can proceed.

Who files, and who owns each part of the dossier

The applicant is the Australian sponsor. TGA’s inclusion process requires the sponsor to be a recognised Australian-based legal entity and to maintain an effective relationship with the manufacturer so required regulatory, technical, clinical and safety information can be produced when TGA asks for it. A service provider can prepare and coordinate the file, but it does not replace the legal responsibilities of the sponsor or manufacturer.

Party	Core filing responsibility	What should be available before submission
Manufacturer	Device design, intended purpose, classification inputs, conformity assessment, Essential Principles evidence and technical/clinical support.	Current certificates/evidence, declaration(s), labels, IFU, technical and clinical records, risk documentation and change history as applicable.
Australian sponsor	TBS account, Manufacturer Evidence submission where required, ARTG inclusion application, TGA correspondence and continuing sponsor obligations.	Authority from the manufacturer, accurate product data, access to supporting documents and an internal escalation contact.
Registration service / consultant	Build the filing map, check consistency, prepare TBS-ready data, coordinate submission and manage evidence requests.	A documented scope showing what is filing execution versus strategic advice or sponsor representation.
TGA	Preliminary assessment, possible application audit and decision on inclusion.	TGA may request supporting information beyond what is attached at lodgement.

If the main issue is choosing the regulatory strategy rather than executing a known route, use the TGA medical device registration consultant page. If the manufacturer needs an Australian entity to hold the sponsor role, see the Australian TGA sponsor service page.

Build the application dossier before submission

A reliable filing pack is assembled outside TBS first, then mapped into the portal. The exact attachment set varies by class and evidence pathway, but the working dossier should let the sponsor answer every application field and produce supporting records without reconstructing the file under deadline.

Identity and grouping: sponsor legal details, manufacturer identity, device class, GMDN term/code, intended purpose and the ARTG “kind” grouping; UPI where applicable.
Manufacturer Evidence: the accepted evidence record in TBS where the route requires it, supported by current conformity assessment or recognised overseas market-authorisation documentation.
Declarations: manufacturer declaration of conformity and any route-specific declarations or certificates required for the application.
Product information: labels, packaging, instructions for use, product manuals, images and promotional material that accurately reflect the intended purpose and claims.
Safety and performance support: evidence of compliance with the Essential Principles and, depending on risk and device type, clinical evidence, risk management material and other technical documentation.
Australian-specific controls: sponsor identification, applicable UDI readiness, local post-market contacts and any conditions or data needed for the Australian entry.

Not every document in this working dossier is necessarily uploaded with every application. Some information must instead be kept available because TGA may request it during assessment, audit or post-market review.

Submission workflow from readiness check to ARTG inclusion

Confirm that the product is in scope as a medical device and that an ordinary ARTG inclusion is the correct route.
Confirm the Australian sponsor and ensure the sponsor has TBS access and manufacturer authority.
Lock the Australian classification, intended purpose, GMDN term and proposed “kind of device” grouping.
Choose the conformity-assessment / comparable-overseas-regulator evidence route and identify application-specific attachments.
Submit Manufacturer Evidence where required and wait until it is accepted and available in TBS.
Complete the inclusion application using data reconciled against the declaration, certificates, labels and IFU.
Submit the application and pay the applicable TGA application fee. Do not rely on a fixed fee copied from an old webpage; the applicable fee should be checked at filing.
Monitor TBS and email for preliminary-assessment outcomes, requests or audit selection, and answer any request from the controlled dossier.
After successful inclusion, verify the ARTG entry and certificate, then hand over the post-market compliance file.

Pre-submission filing gate: what must be green before payment

Check	Green condition	Stop condition
Sponsor/TBS	Correct Australian sponsor, active TBS access and authority from manufacturer.	Foreign manufacturer expects to file directly, or sponsor identity is still changing.
Classification and intended purpose	Australian class is documented and consistent with claims and IFU.	Class was copied from another jurisdiction without checking Australian rules.
Kind/GMDN	Grouping attributes and GMDN term match the device actually being supplied.	Models with materially different intended purpose, risk profile or grouping attributes are being forced into one entry.
Regulatory evidence	Required Manufacturer Evidence is accepted and current; application-specific evidence is ready.	Certificate scope, manufacturer name, device scope or evidence status does not match the application.
Application consistency	Declaration, certificates, labels, IFU and TBS answers tell the same regulatory story.	Conflicting intended purpose, manufacturer, class, GMDN or model information appears across documents.
UDI where applicable	Current Australian UDI obligations for the device class and supply date have been checked.	For a device already subject to mandatory UDI, labelling/data obligations have been left for “after registration”.

Common refusal, delay and audit triggers

TGA can refuse an application at preliminary assessment where statutory application requirements are not met. Operationally, many preventable problems arise from inconsistency rather than the absence of a single document.

Using the wrong application path or class, or omitting prescribed information or attachments.
Submitting before required regulatory evidence is accepted, current and correctly linked.
Providing false, misleading or internally inconsistent information in the application.
Mismatch between intended purpose, classification, GMDN grouping, declaration, certificate scope, labels or IFU.
Assuming CE marking, FDA clearance or another overseas authorisation automatically creates an Australian ARTG entry. Overseas evidence may support the pathway, but Australian inclusion remains a separate regulatory step unless an exemption applies.
Being selected for audit without a controlled response pack: labels, technical documentation, clinical evidence, risk management and other requested records must be retrievable and consistent.

Decision points and what continues after inclusion

After lodgement and payment, the application first has to pass preliminary assessment. The next outcome may be inclusion, selection for audit, refusal, or withdrawal at the sponsor’s request before a decision. If TGA selects an application for audit, the sponsor must provide the requested supporting material and, where applicable, pay an assessment fee.

Successful ARTG inclusion is not the end of the regulatory file. The sponsor must continue to meet conditions of inclusion and post-market obligations, maintain access to evidence, manage safety information and adverse-event responsibilities, and keep the manufacturer–sponsor information flow working. Changes to the manufacturer, evidence, intended purpose, device grouping or other regulated attributes must be screened before implementation to determine whether an update, variation, new application or other TGA action is required.

Australia’s UDI regime is now part of this lifecycle control. Mandatory UDI compliance began on 1 July 2026 for Class III and Class IIb medical devices, with later dates for other in-scope classes. The applicable transition rules must be checked for the specific device rather than inferred from the ARTG inclusion date alone.

What a filing-execution service should hand back to the client

Route memo: confirmed ARTG route, classification assumptions, “kind” grouping and evidence pathway.
Dossier index: a version-controlled list of every source document, status, owner and TBS use.
TBS-ready data sheet: the exact sponsor, manufacturer, classification, GMDN, intended-purpose and application answers used for lodgement.
Submission record: application identifier, invoices/payment status, lodged attachments and a dated correspondence log.
Audit-response pack: a pre-indexed set of technical, clinical, labelling and risk records that can be produced quickly if TGA asks.
Post-inclusion handover: ARTG entry/certificate, conditions, UDI status, evidence-expiry watchpoints, vigilance contacts and change-control triggers.

This execution record is the practical difference between “we submitted a form” and a registration file that can be defended and maintained.

Official TGA sources

FAQ

Can a foreign manufacturer submit the ARTG inclusion application directly?

The ordinary inclusion application is made by the Australian sponsor. TGA states that a sponsor must be a recognised Australian-based legal entity. A foreign manufacturer therefore needs an appropriate sponsor relationship rather than treating the filing as a direct foreign-manufacturer application.

Does CE marking or FDA clearance remove the need for TGA registration?

No. Comparable overseas evidence can support an Australian pathway, but it does not itself create an ARTG inclusion. Unless an exclusion, exemption or another lawful access pathway applies, the Australian sponsor still needs the relevant ARTG inclusion.

Can several models be covered by one ARTG entry?

Sometimes. The answer depends on whether the products meet the Australian definition of the same “kind of medical device”. Sponsor, manufacturer, classification and GMDN are core grouping attributes, and high-risk groupings can also depend on UPI. Do not group products only because they share a brand family.

Does TGA review the full technical file for every application?

Not necessarily. TGA uses risk-based processes and may include a device without a full application audit, or select an application for audit. The sponsor should nevertheless have the supporting technical, clinical, labelling and risk information under control because TGA may request it.

What should be ready before the application fee is paid?

At minimum, the sponsor/TBS setup, Australian classification, intended purpose, “kind” grouping, GMDN, required accepted Manufacturer Evidence, prescribed attachments and a cross-check of declaration/certificates/labels/IFU should be complete. For devices already in scope of mandatory Australian UDI, UDI readiness must also be checked before supply.